MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences collaborate on antibody drug development
The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.
MRC Technology and Institut Pasteur of Shanghai, Chinese Academy of Sciences (IPS-CAS) have signed a collaboration agreement to develop new therapeutic antibodies from research originating in China.
IPS-CAS is well regarded for their cutting-edge research in infectious diseases and capability generating antibodies and MRC Technology, a medical research charity, has proven expertise in progressing promising research towards the clinic. The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.
Monoclonal antibody-based drugs have been established as one of the most successful therapeutic strategies for the treatment of infectious diseases, cancers and autoimmune diseases.
“The promise of immune check-point antibodies and broadly neutralising antibodies against pathogens brings a boom in research and research development across the world, which makes this collaboration all the more significant and important,” said Professor Sun Bing, the Director of IPS-MRCT Joint Centre for Therapeutic Antibodies.
Dr Dave Tapolczay, Chief Executive, MRC Technology, said: “MRC Technology uses the potential of science to change lives. Our projects have led to several approved drugs which are improving patients’ lives across the world. Biomedical research is flourishing in China and we are pleased to work with IPS to progress the science towards worldwide benefit.”
The Chinese Academy of Sciences is proposing to set up a new centre to manage intellectual property and will also draw on MRC Technology’s expertise in IP development, protection and management in this venture.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance